Source Plasma Safety
|
|
- Daisy Allen
- 6 years ago
- Views:
Transcription
1 Source Plasma Safety Plasma May 15-19, 2017 George Schreiber, ScD, PPTA Director, Epidemiology
2 Three components: Plasma Product Safety Donor Quality Manufacturing Pool Quality Fractionation Process Safe High Quality Plasma Products Slide 2
3 Relative Risk Plasma Quality Steps Donor selection Testing donations NAT testing Inventory Hold (where applicable) Virus inactivation / removal steps Finished product From Donor to Patient Therapy Slide 3
4 Plasma Quality Steps Important Plasma Quality Steps Donor Screening Medical history and physical examination (protects donor health and reduces recipient risk) Laboratory Testing Qualified Donors (Source Plasma) 60 Day Inventory Hold (Source Plasma) Residual Risk Assessments Epidemiological [viral marker] standards Slide 4
5 Donor Selection National Donor Deferral Registry (U.S. Source Plasma) Reactive donors entered in national database for HIV, HBV, HCV Prospective donors must be checked in database before allowed to donate Community- Based Donor Standard No donors without permanent address. Donors must reside within defined recruitment area Valild photo ID Donor Education Standard Donors must be educated regarding HIV/AIDS Assessment of comprehension for new donors Slide 5
6 International Quality Plasma Program Donor Selection Standards Lowered Risk Viral Marker Standard Center s viral marker rates compared to industry average Centers repeatedly exceeding Alert Limits subject to lose IQPP certification Qualified Donor Standard New donors must pass 2 medical screenings and testing Reactivated donors (Qualified with > 6 month lapse) must requalify Slide 6
7 Quality Standards of Excellence, Assurance & Leadership QSEAL Standards Lowered Risk Inventory Hold Standard Plasma held in inventory for at least 60 days after donation Allows for interdetection and destruction of plasma based on post-donation disqualifiers NAT Testing Standard Requires NAT for HIV, HBV and HCV at minipool and at First Homogeneous Pool level Requires in-process testing for HAV and Parvovirus B19 Slide 7
8 Viral Marker Standard A statistically reliable system to ensure collection from quality Source Plasma collection centers, based on viral marker rates. In place for over a decade Serves as a guide for quality improvement Marker specific for HIV, HCV, and HBV Academic peer-reviewed Approach endorsed by FDA Slide 8
9 Viral Marker Alert Limits Alert Levels allow for identification of centers with higher than expected viral positivity rates. Allows for continuous epidemiological evaluation at individual plasma collection centers together with an annual update of the assessment. Reference rates based on overall industry averages for donors contributing to the pool, measured in a defined time period with the most appropriate testing technology. Slide 9
10 Donations (10 6 ) 13,233,773 13,824,545 12,644,462 10,317,674 10,368,480 12,442,214 15,326,821 18,817,869 22,028,860 19,807,473 23,573,488 26,214,019 29,391,097 32,550,293 35,464,612 38,296, Slide 10
11 # Centers Number U.S. Centers 600 Number of US Source Plasma Centers Slide 11
12 Qualified Donor Positivity Rates Slide 12
13 Residual Risk Estimates of a potentially infectious unit being released for fractionation or transfusion Slide 13
14 Residual Risk Residual Risk of Viral Agent Entering the Manufacturing Pool The presence of certain viruses in asymptomatic donors who are negative on the screening tests (window period donations) constitutes the major risk of viruses entering the fractionation process. The Residual Risk is the estimated probability of a potentially infectious plasma unit entering the manufacturing pool. Accounts for industry inventory hold. Used to assess the impact of industry safety initiatives. Can be used to estimate pool viral load. The viruses of concern are: HCV, HIV, and HBV. Slide 14
15 Residual Risk / 10 6 Donations HIV and HCV Residual Risk HIV HCV Slide 15
16 Residual Risk / 106 Donations HBV Residual Risk Slide 16
17 Odds of Dying: What we Should Fear Odds versus Risk Odds per 1,000,000 Cancer (lifetime) 142,857 Hospital Infection (lifetime) 26,316 Complications of Medical Surgical Care (lifetime) 762 Exposure to Forces of Nature (lifetime) 574 Drowning in a Bathtub (lifetime) 90 Killed by a dog (lifetime) 9 Asteroid Impact (Lifetime) 5 Struck by Lighting (year) 2.5 Versus Risk of: A Potentially Infectious Source Plasma Unit Making it to the Manufacturing Pool 1-8 Slide 17
18 Key Points to Remember Residual risk for Source Plasma not the same as RR for whole blood. WB is risk of transmission by transfusion. Source Plasma is risk of a POTENTIALLY contaminated unit entering manufacturing pool. Potentially contaminated units have detection levels below that of the NAT test. All manufactured Source Plasma derived products have virus removed or inactivated. Residual risk of transmission is then reduced to zero. Slide 18
19 Effectiveness of Inventory Hold in Reducing Residual Risk (per 10 6 ) Inventory Hold 2014 Residual Risk 2015 Residual Risk Hold 0-Day Hold 60-Day No Hold /60-Day % Reduction Hold 0-Day Hold 60- Day No Hold /60 days % Reduction HIV HCV HBV Slide 19
20 Residual Risk Percent Percent of Residual Risk (Incidence Donor / Total) No Hold 60-day Hold HIV HCV HBV Percent of Residual Risk due to Incidence donors, by Inventory Hold. Slide 20
21 I ll pause for a moment so you can let this information sink in. Slide 21
22 Viral Load in Manufacturing Pool Viral Load Detection limit (96 minipool) Residual Risk Chance of WP donation in pool Viral Load 1 WP/pool (6000 donations) Viral Load if ALL donations are WP HCV 675 IU/mL IU/mL 675 IU/mL HIV 4420 IU/mL IU/mL 4420 IU/mL HBV 220 IU/mL IU/mL 220 IU/mlL Slide 22
23 Effects on Viral Load Effect of Viral Inactivation / Removal on Viral Load Viral Load (IU/mL) 1 WP donation in pool All WP donations in pool 9 logs reduction 12 logs reduction 9 logs reduction 12 logs reduction HCV 1.1 / / / / HIV 7.4 / / / / 10 9 HBV 4.0 / / / / Assuming one WP donation in the manufacturing pool, viral load reduction is complete. Even assuming all donations are WP, an impossible scenario, viral inactivation/removal steps guarantee product safety. Slide 23
24 Inherent Truths Demographic variations in infectious disease prevalence and incidence exist. Viral removal and inactivation are key to ensuring the safety of fractionated plasma products. Risk of a potentially infectious unit entering the plasma manufacturing pool is small. Viral inactivation and removal significantly reduces the residual risk in finished plasma products. Slide 24
25 Differences exist in how patients, regulators and industry view the importance of donor quality compared to product quality but all stakeholders recognize the importance of product safety. Plasma derived products have never been safer as a result of the rigorous efforts of the industry to ensure quality donors, sensitive testing, and virus inactivation/removal technologies. Inherent Truths There has been no confirmed case of transmission of viral infection in more than two decades, attesting to the safety of plasma derived products. Slide 25
donors and collecting blood and plasma in for-profit or a not for profit environment
Remunerated versus non-remunerated donors and collecting blood and plasma in for-profit or a not for profit environment ISBT Amsterdam, June 4, 2013 Jan M. Bult President PPTA PATIENT CENTEREDNESS IT
More informationIQPP Qualified Donor Standard
IQPP Qualified Donor Standard Background The is part of a series of standards that comprise the Plasma Protein Therapeutics Association (PPTA) IQPP Standards Program. PPTA's Voluntary Standards Program
More informationQSEAL Recovered Plasma Specification
QSEAL Recovered Plasma Specification Background The is part of a series of standards that comprise the Plasma Protein Therapeutics Association (PPTA) QSEAL Standards Program. PPTA's Voluntary Standards
More informationWHO Parvovirus B19 Genotype Panel
WHO Parvovirus B19 Genotype Panel Mei-ying W Yu, PhD SoGAT XXII Rome, 14-15 April 2011 1 st WHO International Reference Panel for Parvovirus B19 Genotypes In Oct 2009, a plasma-derived parvovirus B19 (B19V)
More informationImpact of multi-dye multiplex technology on testing algorithm
Impact of multi-dye multiplex technology on testing algorithm Lydia Blanco. Mª Isabel Gonzalez-Fraile Centro de Hemoterapia y Hemodonación de Castilla y León, España TTI EPIDEMIOLOGICAL DATA IN SPAIN NAT
More informationPlasma for fractionation: South African Plasma Requirements
Plasma for fractionation: South African Plasma Requirements Dr Jeh-han Omarjee Head: Microbiological Sciences NBI is a "not for profit" company committed to providing safe, cost effective, quality medicinal
More informationZpracování lidské plazmy
Zpracování lidské plazmy a bezpečnost koncentrátů plazmových pa pote proteinů ů MUDr. Ivan Vonke, OKH, Nemocnice Č.Budějovice, a.s. Raw material blood Hormons Proteins More than 120 plasma proteins 70-80g/Liter
More informationLookback studies to assess viral risks The French experience
Lookback studies to assess viral risks The French experience 2000-2012 S Laperche 1, MF Leconte des Floris 2, J Pillonel 3, L Hauser 2, C Lefort 2, JY Py 2, I Hervé 2, R Djoudi 2 For the French haemovigilance
More informationDraft Agreed by Biologics Working Party December Draft Agreed by Blood Products Working party December 2010
15 December 2011 EMA/CHMP/BWP/360642/2010 rev. 1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the warning on transmissible agents in summary of product characteristics (SmPCs) and
More informationGuidance for Industry
Guidance for Industry Use of Nucleic Acid Tests on Pooled and Individual Samples from Donors of Whole Blood and Blood Components (including Source Plasma and Source Leukocytes) to Adequately and Appropriately
More informationtransfusion-transmissible HCV and HIV in Italy Haemovigilance and the residual risk of
Haemovigilance and the residual risk of transfusion-transmissible Giuliano Grazzini, MD National Blood Centre, National Institute of Health, Rome, Italy & International Federation of Blood Donor Organizations
More informationHepa%%s E Virus Is it a Concern?
IPFA/PEI 17 th Workshop on Surveillance and Screening of Blood Borne Pathogens 26-27 May 2010, The Regent Esplanade Zagreb Hotel, Zagreb, Croa%a Hepa%%s E Virus Is it a Concern? Keiji Matsubayashi Hokkaido
More informationQualified Donor Standard. Implemented 1997 Revised Version 3.0
Implemented 1997 Revised 2006 Version 3.0 IQPP Contents I. Background... 3 II. Definitions... 3 III. Standard... 3 IV. Inspection and Compliance Verification... 4 Appendix 1: Questions & Answers... 5 Page
More informationPathogen Safety Monograph. Baxter BioSurgery Products [North America]
Pathogen Safety Monograph Baxter BioSurgery Products [North America] In the production of plasma-derived therapeutics, patient safety is of paramount importance. Pathogen Safety Monograph for Baxter BioSurgery
More informationImpact of Testing Strategies to Reduce Transmission Risk for HBV. Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013
Impact of Testing Strategies to Reduce Transmission Risk for HBV Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013 Overview of SANBS SANBS is a private not for profit company
More informationPathogen Safety and BSE / variant CJD
Pathogen Safety and BSE / variant CJD Thomas R. Kreil, Global Pathogen Safety Parenteral Drug Industry Plasma Protein Industry Summit September 7, 2017; Beijing Pathogen Safety Those who cannot remember
More informationReporting from Council of Europe member states on the collection, testing and use of blood and blood components in Europe The 2006 Survey
Reporting from Council of Europe member states on the collection, testing and use of blood and blood components in Europe The 2006 Survey This questionnaire consists of three sections: A. Collection and
More information23 November Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
23 November 2016 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Submitted via http://www.regulations.gov Re: Docket No. FDA-2016-N-1502,
More informationObjectives. Methods. Results. Economic
Octaplas Compared with Fresh Frozen Plasma to Reduce the Risk of Transmitting Lipid-Enveloped Viruses: An Economic Analysis and Budget Impact Analysis [Adapted from Membe SK, Coyle D, Husereau D, Cimon
More informationScreening donors and donations for transfusion transmissible infectious agents. Alan Kitchen
Screening donors and donations for transfusion transmissible infectious agents Alan Kitchen Aim Not to teach you microbiology To provide and awareness of the big picture To provide an understanding of
More informationJune 8, Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
June 8, 2018 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Submitted via http://www.regulations.gov Re: Docket No. FDA 2016 D 0545,
More informationINDONESIAN EXPERIENCE IN PRODUCING MINIPOOL CRYOPRECIPITATE. Yuyun SM Soedarmono
INDONESIAN EXPERIENCE IN PRODUCING MINIPOOL CRYOPRECIPITATE Yuyun SM Soedarmono 1 BACKGROUND Indonesia has more than 240 million population and approximately 25,000 hemophilia A patients Hemophilia A patients
More informationThe cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P
The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P Record Status This is a critical abstract of an economic evaluation that meets
More informationA. Anti-HIV-1/2, HIV NAT Lookback: for those identified blood and blood components collected:
PURPOSE: MATERIALS: To outline a procedure for removing, recalling and/or correcting blood products that do not meet the requirements of the FDA, AABB, or the blood center. Recall/Market Withdrawal Form
More informationGuidance for Industry
Guidance for Industry Lookback for Hepatitis C Virus (HCV): Product Quarantine, Consignee Notification, Further Testing, Product Disposition, and Notification of Transfusion Recipients Based on Donor Test
More informationUsing Donor Human Milk in Extremely Premature Infants
Using Donor Human Milk in Extremely Premature Infants Introduction Scott Eaker, Vice President of Quality and Regulatory Affairs Scott Elster, Chief Executive Officer David Rechtman, MD, Chief Medical
More informationTransfusion Risk for Hepatitis B, Hepatitis C and HIV in the State of Santa Catarina, Brazil,
236 BJID 2004; 8 (June) Transfusion Risk for Hepatitis B, Hepatitis C and HIV in the State of Santa Catarina, Brazil, 1991-2001 Emil Kupek Department of Public Health, Federal University of Santa Catarina,
More informationBLOOD DONATION AFTER ACUPUNCTURE: A JUSTIFIED DEFERRAL?
BLOOD DONATION AFTER ACUPUNCTURE: A JUSTIFIED DEFERRAL? What if your patients want to donate blood? Are you aware that patients undergoing Acupuncture treatment, according to international guidelines,
More informationBLOOD SAFETY STATUS IN INDONESIA. Yuyun Soedarmono Chairman of the Indonesian Association of Transfusion Medicine
BLOOD SAFETY STATUS IN INDONESIA Yuyun Soedarmono Chairman of the Indonesian Association of Transfusion Medicine OUTLINE Background Blood services in Indonesia Regulation related to blood safety in Indonesia
More informationANNALS OF HEALTH LAW Advance Directive VOLUME 23 SPRING 2014 PAGES
ANNALS OF HEALTH LAW Advance Directive VOLUME 23 SPRING 2014 PAGES 101-112 United States Blood Donor Policy on Gay Men: Adopting an Italian Individual Risk Assessment Policy Melissa Kong* I. INTRODUCTION
More informationRISK OF DISEASE TRANSMISSION FROM ORGAN DONORS PATIENT INFORMATION GUIDE
Receiving an organ transplant carries many risks, including the risk of getting a disease from the June 2017 donor. This is true for every organ we transplant. BC Transplant makes every effort to minimize
More informationChanging eligibility criteria for MSM: The Canadian Perspective
Changing eligibility criteria for MSM: The Canadian Perspective Mindy Goldman MD Canadian Blood Services ASFA & WAA Joint Meeting, San Francisco April 4, 2014 Outline - Historical background - International
More informationRoutine NAT-screening for West Nile Virus Infections in Germany: Being prepared
Routine NAT-screening for West Nile Virus Infections in Germany: Being prepared R. Thermann, W. K. Roth IPFA / PEI 18 th international workshop on Surveillance and screening of blood borne pathogens Budapest,
More information2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies
2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies Submitted by: Malaysia Policy Dialogue and Workshop on Attaining a Safe and Sustainable Blood Supply Chain Manila, Philippines 30 September 1
More informationChange in deferrals for men who have sex with men: Assessing the risk of HIV transmission by transfusion
Change in deferrals for men who have sex with men: Assessing the risk of HIV transmission by transfusion Josiane Pillonel, Rachid Djoudi, Florence Lot, Chistophe Martinaud, Claire Sauvage, Marie Jauffret-Roustide,
More informationOverview of Blood Transfusion System of Iran:
Report Article Overview of Blood Transfusion System of Iran: 2002-2011 AM Cheraghali High Institute for Research and Education on Transfusion Medicine, Iran Blood Transfusion Organization and University
More informationTRANSFUSION ASSOCIATED DISEASE, RECALL, OR COMPLICATION INVESTIGATION POLICY I. FATALITIES AND COMPLICATIONS ASSOCIATED WITH TRANSFUSION:
I. FATALITIES AND COMPLICATIONS ASSOCIATED WITH TRANSFUSION: A. TRANSFUSION RELATED FATALITY: FDA and MEDIC must be notified immediately, and subsequently in writing, when a possible transfusion related
More information[Submitted Electronically]
[Submitted Electronically] Dr. Matthew J. Kuehnert, Director Office of Blood, Organ, and Other Tissue Safety Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic Infectious
More informationViral Hepatitis. WHO Regional Office for Europe July 2013
Viral Hepatitis WHO Regional Office for Europe July 2013 What is Hepatitis? Hepatitis is a viral infection that causes inflammation of the liver There are five main types of viral hepatitis: A, B, C, D,
More informationWHO GUIDELINES ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA
ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 21 October 2016 WHO GUIDELINES ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA
More informationA comparison of the removal of parvovirus B19 and model parvoviruses from plasma products by virus filtration
A comparison of the removal of parvovirus B19 and model parvoviruses from plasma products by virus filtration Shirley Stagg, Samantha Fernando, Amy Shackell, Peter Roberts, Joan Dalton Bio Products Laboratory,
More informationFDA Reentry Guidance
FDA Reentry Guidance T. cruzi - Chagas, Hepatitis C and HIV Wednesday 6/6/18 Doug Denyer O Dina Hurlburt, SBB(ASCP)CM Outline Impact to Clients Review of FDA Guidance Documents Reentry Request Process
More informationCenter for Biologics Evaluation and Research
Center for Biologics Evaluation and Research Current Activities Future Directions Washington, DC January 25, 2010 Karen Midthun, MD Acting Director, CBER CBER Our Mission To ensure the safety, purity,
More informationPlasma Fractionation Issues for Developing Countries DR YASMIN AYOB
Plasma Fractionation Issues for Developing Countries DR YASMIN AYOB Plasma Fractionation Evolved from a medical service to a global manufacturing industry Involves sophisticated industrial process High
More informationpatients with blood borne viruses Controlled Document Number: Version Number: 4 Controlled Document Sponsor: Controlled Document Lead:
CONTROLLED DOCUMENT Procedure for the management of patients with blood borne viruses CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Version Number: 4 Controlled Document Sponsor: Controlled
More informationProduct Monograph. Key Scientific Information
Product Monograph Key Scientific Information Ko ate -DVI (Double Viral Inactivation) Infusion of more than 2 billion IUs worldwide with no confirmed cases of viral transmission.* Talecris is a leader in
More informationPublic Health, Infections and Transplantation
Public Health, Infections and Transplantation Dr Kerry Chant Chief Health Officer & Deputy Director General Population and Public Health NSW Ministry of Health May2014 Public Health Infection and Transplantation
More informationHIV/AIDS DEPARTMENT GLOBAL HEPATITIS PROGRAMME
HIV/AIDS DEPARTMENT GLOBAL HEPATITIS PROGRAMME Technical considerations and case definitions for VIRAL HEPATITIS SURVEILLANCE Dr Yvan J-F Hutin Global Hepatitis Programme 01 FOUR MAIN HEPATITIS VIRUSES
More informationrisk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV)
Prevention and ResidualR risk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV) Syria Laperche L (Centre National de référence r rence pour les hépatites h B et C en Transfusion)
More informationGuidance for Industry
Guidance for Industry Advisement for the Use of Gen-Probe Procleix Ultrio Plus Assay for NAT Testing on Cadaveric Donors Release Date: 08/03/14 American Medical Education and Research Association 4757
More informationDuration: 12 months May to April
SPECIALIST CERTIFICATE IN TRANSFUSION SCIENCE PRACTICE PROGRAMME OF STUDY OVERVIEW Example only Duration: 12 months May to April This document serves as a general programme overview only. To ensure you
More informationStructure and duties of Blood service
NATIONAL CENTER FOR TRANSFUSION MEDICINE Prevalence of infectious diseases among Mongolian blood donors Namjil Erdenebayar General director of The National Center for Transfusion Medicine, Mongolia NCTM,
More informationTransfusion-transmitted Cytomegalovirus
Transfusion-transmitted Cytomegalovirus Can you confidently abandon CMV seronegative products in the modern era of pre-storage leukoreduction? Jeannie Callum, BA, MD, FRCPC Really? Are we still talking
More informationDepartment of Health and Human Services
Friday, August 24, 2007 Part III Department of Health and Human Services Food and Drug Administration 2 CFR Parts 606 and 60 Current Good Manufacturing Practice for Blood and Blood Components; Notification
More informationResearch Article Decreasing Prevalence of Transfusion Transmitted Infection in Indian Scenario
e Scientific World Journal, Article ID 173939, 4 pages http://dx.doi.org/10.1155/2014/173939 Research Article Decreasing Prevalence of Transfusion Transmitted Infection in Indian Scenario Tulika Chandra,
More informationTGA regulation of local manufacturers of plasma derivatives CSL Behring Australia s overview
IPFA Workshop Session 7: REGULATORY CONSIDERATIONS TGA regulation of local manufacturers of plasma derivatives CSL Behring Australia s overview Mary Lavithis, CSL Behring Australia Presented at: IPFA Asia
More informationAssays to Address Emerging Threats to Blood Safety
Assays to Address Emerging Threats to Blood Safety Jeffrey M. Linnen, Ph.D. Director, Product Development Gen-Probe Incorporated San Diego, CA The IPFA/PEI 17th Workshop on Surveillance and Screening of
More informationNon-reproductive tissues and cells Recommending authority/ association
Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent - legally binding More stringent - recommended Not legally binding and not recommended Non-reproductive tissues and cells
More informationNRL EQAS for NAT: Assessing the variability and performance of molecular assays for clinical pathogens
NRL EQAS for NAT: Assessing the variability and performance of molecular assays for clinical pathogens Vincini GA*, Cabuang LM, Land S, Best SJ NRL London, 12 January 2011 NRL EQAS for NAT HCV Genotyping
More informationThe Alphabet Soup of Viral Hepatitis Testing
The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
PAGE 1 of 5 PURPOSE To provide guidelines on the treatment and care of patients with Hepatitis. POLICY Hepatitis is an injury to hepatic cells and an inflammatory process in the liver. The major causes
More informationGuide to the preparation, use and quality assurance of blood components
Contents Foreword...3 Members of the European Committee (Partial Agreement) on Blood Transfusion... 8 Members of the GTS working group... 22 Members of the TS066 working group... 30 Recommendation No.
More informationArmed Services Blood Program
Armed Services Blood Program Defense Health Board Concerns Regarding the Collection and Transfusion of Non-FDA Compliant Blood Products in Theater Information Brief Defense Health Board 17 August 2009
More informationSIXTY-SECOND WORLD HEALTH ASSEMBLY A62/22 Provisional agenda item April Viral hepatitis. Report by the Secretariat
SIXTY-SECOND WORLD HEALTH ASSEMBLY A62/22 Provisional agenda item 12.17 16 April 2009 Viral hepatitis Report by the Secretariat THE DISEASES AND BURDEN 1. The group of viruses that cause acute and/or chronic
More informationImpact of changing donor demographics on HIV transmission risk: A ten year analysis of individual donation NAT screening
Impact of changing donor demographics on HIV transmission risk: A ten year analysis of individual donation NAT screening IPFA Lisbon 216 Marion Vermeulen Disclaimer Race classifications are described as
More informationGlobal Reporting System for Hepatitis (GRSH) An introduction. WHO Global Hepatitis Programme
Global Reporting System for Hepatitis (GRSH) An introduction WHO Global Hepatitis Programme 2018 Objectives 1. Explain the role of the new reporting system 2. Outline the reporting required from countries
More informationAnnual SHOT Report 2016 Supplementary Information. Chapter 17: Transfusion-Transmitted Infections (TTI)
Annual SHOT Report 2016 Supplementary Information Chapter 17: Transfusion-Transmitted s (TTI) The table below is an excerpt from the full Table 17.3 which can be viewed in the main report. Case reports
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091606 Age 24 Years Gender Male 30/8/2017 92800AM 30/8/2017 94631AM 31/8/2017 90306AM Ref By Final HEATITIS A & B VIRUS EVALUATION HEATITIS A ANTIBODY (ANTI HAV),
More informationAPPROACH TO RISK MANAGEMENT IN MEDICAL PRACTICE: STANDPOINT OF THE BLOOD TRASFUSION*
11 APPROACH TO RISK MANAGEMENT IN MEDICAL PRACTICE: STANDPOINT OF THE BLOOD TRASFUSION* Hisami IKEDA** Asian Med. J. 44(1): 11 21, 2000 Abstract: In the field of blood transfusion, risk management is defined
More informationEMEA WORKSHOP ON VIRAL SAFETY OF PLASMA-DERIVED MEDICINAL PRODUCTS WITH PARTICULAR FOCUS ON NON-ENVELOPED VIRUSES. 13 September 2000 REPORT SUMMARY
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 28 March 2001 CPMP/BWP/BPWG/4080/00 EMEA WORKSHOP ON VIRAL SAFETY OF PLASMA-DERIVED MEDICINAL
More informationRoutine Use of Mini-Pool Nucleic Acid Testing (MP-NAT) Multiplex Assay for Sero-Negative Blood Donors
Journal of the Egyptian Society of Haematology & Research, Vol. 7, No. 2, September: 1-5, 2011 Routine Use of Mini-Pool Nucleic Acid Testing (MP-NAT) Multiplex Assay for Sero-Negative Blood Donors HISHAM
More informationPATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER
Verified with regard to factual content 13.12.2011 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER GAMMA anty-hbs 1000 Immunoglobulinum humanum hepatitidis B Human immunoglobulin against Hepatitis
More informationJuventas SHARING LIFE CONSENT FOR PLASMA INFUSION
Juventas SHARING LIFE Print Name Date of Birth CONSENT FOR PLASMA INFUSION To the Patient or Guardian of the Patient: The purpose of this document is to provide written information as of (month and day),
More informationTransfusion-transmitted HIV from seroconverted blood donors has not been identified in England since the introduction of HIV NAT screening
Transfusion-transmitted HIV from seroconverted blood donors has not been identified in England since the introduction of HIV NAT screening Bhavita Vishram Timeline of introduction of microbiological tests
More informationSurveillance Report 2014
Surveillance Report 2014 Executive summary We are pleased to present the third report for our stakeholders describing infectious disease surveillance. High quality and timely surveillance is key to the
More informationHepatitis C Cure The Invisible Epidemic
Hepatitis C Cure The Invisible Epidemic Iris House 8 Th Annual Face of AIDS Summit Hadiyah Charles Hepatitis Advocacy Manager Harm Reduction Coalition Hepatitis C Basics A virus that can cause chronic
More informationTRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES ADVISORY COMMITTEE MEETING October2010. Issue Summary
TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES ADVISORY COMMITTEE MEETING 28-29October2010 Issue Summary Informational Topic: FDA s Geographic Donor Deferral Policy to Reduce the Possible Risk of Transmission
More informationWORLD HEALTH ORGANIZATION. Blood safety: proposal to establish World Blood Donor Day
WORLD HEALTH ORGANIZATION EXECUTIVE BOARD EB115/9 115th Session 25 November 2004 Provisional agenda item 4.6 Blood safety: proposal to establish World Blood Donor Day Report by the Secretariat 1. Blood
More informationTable 2.1. Cohort Studies of HCV and Hepatocellular Carcinoma
Americas Guiltinan et al. (2008) USA Retrospective cohort of 10259 anti- HCV-positive allogeneic blood donors (6627 men, 3632 women) and 10259 anti-hcv-negative donors (6627 men, 3632 women) matched to
More informationDONOR RECRUITMENT AND PLASMA COLLECTION IN INDONESIA. Yuyun SM Soedarmono Blood Services Committee Ministry of Health of Indonesia 1
DONOR RECRUITMENT AND PLASMA COLLECTION IN INDONESIA Yuyun SM Soedarmono Blood Services Committee Ministry of Health of Indonesia 1 OUTLINE Introduction Challenges to Fulfill Global Demand of Plasma for
More informationKNOWLEDGE INFUSION: FOCUS ON RISK-BASED DECISION-MAKING
KNOWLEDGE INFUSION: FOCUS ON RISK-BASED DECISION-MAKING Permission to Use: Please note that the presenter has agreed to make their presentation available. However, should you want to use some of the data
More informationChapter 17: Transfusion-Transmitted Infections (TTI)
Annual SHOT Report 2014 Supplementary Information Chapter 17: Transfusion-Transmitted s (TTI) The table below is an excerpt from the full Table 17.2 which can be viewed in the main report. Case reports
More informationHot Topics in Tissue Safety
Hot Topics in Tissue Safety 37 th Annual AATB Meeting National Harbor, Maryland 03 October 2013 Scott A. Brubaker, CTBS Chief Policy Officer PHS Guideline for Reducing Human Immunodeficiency Virus, Hepatitis
More informationCase 1. FDA, Legal, and EBAA Medical Standards Panel. Case 1. Case 1 6/25/2012. Samuel B. Barone, M.D. Office of Cellular, Tissue, and Gene Therapies
Case 1 FDA, Legal, and EBAA Medical Standards Panel Samuel B. Barone, M.D. Office of Cellular, Tissue, and Gene Therapies Medical Directors Symposium Eye Bank Association of America Annual Meeting 47 y/o
More informationInformed Consent for Liver Transplant Patients
Informed Consent for Liver Transplant Patients Evaluation Process You will be evaluated with consultations, lab tests and various procedures to determine the medical appropriateness of liver transplant.
More informationSituation of XMRV and Blood Transfusion. Celso Bianco, MD ISBT Working Party on TTID Lisbon, June 19, 2011
Situation of XMRV and Blood Transfusion Celso Bianco, MD ISBT Working Party on TTID Lisbon, June 19, 2011 Lombardi et al. Science 326, 585 (2009) Conclusions: CFS and XMRV XMRV found in 67% of CFS patients
More informationPUBLICATION OF THE SUPERIOR HEALTH COUNCIL No. 9291
PUBLICATION OF THE SUPERIOR HEALTH COUNCIL No. 9291 Sexual risk behaviour and blood donation Part I: Blood donations by MSM This version was validated by the Board on October 2016 1 This advisory report
More informationFact Sheet Blood Collection and Use Hong Kong Red Cross Blood Transfusion Service The Hong Kong Red Cross began its voluntary, nonremunerated blood donation programme to supply blood to all hospitals in
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091650 Age 49 Years Gender Male 29/8/2017 120000AM 29/8/2017 100248AM 29/8/2017 105306AM Ref By Final HEATITIS, VIRAL, COMREHENSIVE ANEL HEATITIS A ANTIBODY (ANTI
More informationKeeping the Blood Supply Safe Current and Future Strategies. Marissa Li, MD
Keeping the Blood Supply Safe Current and Future Strategies Marissa Li, MD Overview Pre-collection Donor Screening Collection Visual Inspection Aseptic Processing Leukoreduction of Apheresis Collections
More informationiphis Case ID #: Reported Date: Reporting Source: Diagnosing Health Unit: Branch Office: Outbreak Number:
Case Investigation Form: Hepatitis C Legend iphis system mandatory Required Case Information (add dates as YYYY-MM-DD) Case s Last Name: Case s First Name: Middle Name: Birth Date: Male Gender: Female
More informationUpdate on Transfusion- Transmitted Infectious Diseases
Update on Transfusion- Transmitted Infectious Diseases Scott Koepsell MD PhD Associate Professor University of Nebraska Medical Center I have no conflicts of interest to disclose. Global changes and the
More informationHEV Assay Development Update
HEV Assay Development Update Jeffrey M. Linnen, Ph.D. Senior Director, Research & Development Hologic Gen-Probe, San Diego, California USA IPFA/PEI 20th International Workshop on Surveillance and Screening
More informationGuidelines on Viral Inactivation and Removal Procedures Intended to Assure the Viral Safety of Human Blood Plasma Products
WORLD HEALTH ORGANIZATION ORGANIZATION MONDIALE DE LA SANTE ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 26 to 30 November 2001 Guidelines on Viral Inactivation and Removal Procedures
More informationRECALL / EVENT INVESTIGATION & PATIENT LOOK BACK
RECALL / EVENT INVESTIGATION & PATIENT LOOK BACK Federal, State and AABB requirements for nonconforming product investigation and recipient look back for adverse impact Stacy Ralston MPH, CLS (ASCP), RAC
More informationHEPATITIS C, ACUTE CRUDE DATA. Number of Cases 5 Annual Incidence a LA County 0.05 California b 0.10 United States b 0.68 Age at Diagnosis Mean 38
2016 Annual Morbidity Report HEPATITIS C, ACUTE a Rates calculated based on less than 19 cases or events are considered unreliable b Calculated from: CDC. Notice to Readers: Final 2016 Reports of Nationally
More informationExploring the risks of liver cancer after successful treatment for hepatitis C virus
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Exploring the risks of liver cancer after successful treatment for hepatitis C virus 11 June 2013 In Canada and other high-income countries,
More informationPatient Name: MRN: DOB: Treatment Location:
Page 1 of 5 I. TO (Required) This Section is required to be completed by all patients who undergo kidney transplant surgery. I hereby consent to and authorize Dr. and his/her assistant(s), including supervised
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN NORMAL IMMUNOGLOBULIN FOR SUBCUTANEOUS AND INTRAMUSCULAR USE (CPMP/BPWG/282/00)
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 25 July 2002 EMEA/ COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN NORMAL IMMUNOGLOBULIN
More information